Drug intelligence / Profile preview

SCN-001

Development stage: Unknown
Lead developer: SciCann Therapeutics
Modality: Small Molecules

Overview

SCN-001, also known as "Steady Stomach," is a cannabidiol (CBD) combination therapy developed by SciCann Therapeutics in strategic R&D partnership with FSD Pharma. It is currently in Phase 1/2 clinical development for the treatment of irritable bowel syndrome (IBS), chronic pain, and fibromyalgia. The therapy has received a positive report from the Patent Cooperation Treaty's International Search Authority, confirming its novelty and inventiveness. FSD Pharma holds exclusive Canadian distribution rights for SCN-001.

Brand names: Steady Stomach

Targets

CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))FAAH

Beyond the preview

Go deeper on SCN-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCN-001.

Explore the full profile